Search Within

Shanu Modi

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (37)
  2. Journal Article (23)
  3. Review (2)
Groups
  1. Breast Medicine Service (62)
  2. Department of Medicine (62)
  3. GSK Faculty (62)
  4. Human Oncology and Pathogenesis Program (62)
  5. Solid Tumor Oncology Division (62)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (53)

More Groups

People
  1. Sarat Chandarlapaty (49)
  2. Clifford Hudis (34)
  3. Sujata Patil (24)
  4. Larry Norton (21)
  5. David Solit (16)
  6. Chau Dang (15)

More People

Years
  1. 2024 (6)
  2. 2023 (2)
  3. 2022 (3)
  4. 2021 (4)
  5. 2020 (4)
  6. 2019 (3)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Cancer Research (15)
  3. Clinical Cancer Research (5)
  4. Breast Cancer Research and Treatment (3)
  5. npj Breast Cancer (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (22)
  2. American Association for Cancer Research (20)
  3. Nature Publishing Group (6)
  4. Elsevier Inc. (3)
  5. Oxford University Press (3)
  6. Springer (3)

More Publishers

Results (62)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Journal Article

    Chandarlapaty, S.; Sakr, R. A.; Giri, D.; Patil, S.; Heguy, A.; Morrow, M.; Modi, S.; Norton, L.; Rosen, N.; Hudis, C.; more...
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Combined inhibition of mTORC1 with temsirolimus and HER2 with neratinib: A phase I/II study in patients with metastatic HER2-amplified or triple-negative breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Seidman, A. D.; Modi, S.; Dickler, M.; Drullinsky, P.; Syldor, A.; Sujata, P.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • A phase II trial of ganetespib: Efficacy and safety in patients (pts) with metastatic breast cancer (MBC)
    Meeting Abstract

    Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Moynahan, M. E.; D'Andrea, G.; Haque, S.; more...
    Cancer Research (2011)

    Fulltext@MSK | Save
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Targeted therapy for human epidermal growth factor receptor 2-positive breast Cancer: Can there be too many active drugs?
    Journal Article

    Chandarlapaty, S.; Modi, S.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with Her2-positive trastuzumab-refractory metastatic breast cancer (MBC): Phase 2 trial
    Meeting Abstract

    Modi, S.; Stopeck, A.; Kinden, H.; Sugarman, S.; Ma, W.; Solit, D.; Kersey, K.; Johnson, R.; Hannah, A. L.; Hudis, C.
    Breast Cancer Research and Treatment (2007)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results
    Meeting Abstract

    Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save